ImageneBio, Inc.

IMA

US45175G2075

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 14:41:19 2025-12-09 EST			5-day change	1st Jan Change
6.530 ^USD	-0.15%		+5.15%	-66.77%

11-25	Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target	MT
11-12	ImageneBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Ikena Shareholders Approve Merger With Inmagene

Published on 07/15/2025 at 05:16 pm EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about ImageneBio, Inc.

11-25	Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target	MT
11-12	ImageneBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	ImageneBio, Inc. Appoints Joseph P. Slattery to the Board, Effective November 1, 2025, and as Chair of the Audit Committee of the Board, Effective November 18, 2025	CI
10-29	Miragene Inc. Announces Extension of Key Service Agreement	CI
10-29	Imagenebio Inc elects not to renew agreement with Miragene - SEC filing	RE
10-24	Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target	MT
10-22	ImageneBio, Inc. Appoints Kristin Yarema as Interim Principal Financial Officer, Effective October 21, 2025	CI
10-10	ImageneBio, Inc. Announces Resignation of Jotin Marango as Principal Financial Officer, Effective October 20, 2025	CI
10-10	ImageneBio, Inc. Announces Resignation of Jotin Marango as Chief Financial Officer, Effective October 20, 2025	CI
07-30	Imagenebio Insider Bought Shares Worth $7,999,924, According to a Recent SEC Filing	MT
07-25	Inmagene Biopharmaceuticals Co. Ltd. completed the acquisition of Ikena Oncology, Inc. from entities affiliated with Atlas Venture L.P., entities affiliated with OrbiMed Advisors LLC, Omega Fund VI, L.P., managed by Omega Fund Management, LLC and others in a reverse merger transaction.	CI
07-25	Wedbush Cuts Price Target on Ikena Oncology to $23 From $25, Keeps Neutral Rating	MT
07-24	Ikena Oncology, Inc. announced that it has received $75 million in funding from a group of investors	CI
07-24	Ikena Oncology, Inc.(NasdaqGM:IKNA) dropped from NASDAQ Composite Index	CI
07-24	Ikena Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
07-15	Ikena Shareholders Approve Merger With Inmagene	MT
07-15	Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals	CI
07-15	Ikena Oncology announces stockholder approval of merger with Inmagene Biopharmaceuticals	RE
07-11	Ikena Oncology Provides Information to the Shareholders	CI
06-16	BML Investment Partners, L.P. Issues a Letter to the Board of Ikena Oncology, Inc	CI
05-08	Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
03-17	ImageneBio, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-06	Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
01-07	Foundery Innovations, Inc. acquired Worldwide Rights for Three Clinical-Stage Immune Tuning Therapies of Ikena Oncology, Inc..	CI
12-23	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.

Employees

Sector

Biotechnology & Medical Research

More about the company